Apimeds Pharmaceuticals US, Inc.
APUS NYSE Pharmaceutical Preparations Financials FY2023–FY2025
Last close · Oct 23, 2026
$2.89
8.5%What Apimeds Pharmaceuticals US, Inc. does
No business description yet.
- Legal name
- Apimeds Pharmaceuticals US, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · May 4, 2026
- Accession · CIK
- 0001213900-26-051139
0001894525
Revenue and margins
Apimeds Pharmaceuticals US, Inc. had — of revenue in fiscal 2025.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was −$9.0M in fiscal 2025, — of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Apimeds Pharmaceuticals US, Inc. returned — to shareholders in fiscal 2025. The diluted share count rose 37.7%.
Balance sheet
Cash, debt and the ratios that show how comfortably Apimeds Pharmaceuticals US, Inc. can carry it.
| Fiscal year end | FY23 | FY24 | FY25 |
|---|---|---|---|
| Cash and short-term investments | $0.4M | $0.0M | $3.6M |
| Interest coverage | −19.6x | −10.8x | −42.1x |
| Current ratio | 3.4x | 0.0x | 1.3x |
| Quick ratio | 3.4x | 0.0x | 1.3x |
| Total assets | $0.4M | $0.0M | $164M |
| Total liabilities | $0.4M | $1.4M | $10.8M |
| Shareholders' equity | $0.0M | −$1.4M | $153M |
| Net debt (− = net cash) | — | — | — |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | ✕ | ✕ | ✕ |
| Cash from operations is positive | ✕ | ✕ | ✕ |
| Return on assets rose | — | ✕ | ✓ |
| Cash from operations exceeds net income | ✓ | ✓ | ✕ |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | — | ✕ | ✓ |
| Share count didn't rise | — | — | ✕ |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | — | — | — |
| F-score | — / 3 | — / 5 | — / 6 |
| Accruals ratio | −35.5% | −301.7% | 3.6% |
| Altman Z'' | −30.35 | −2,254.46 | 14.30 |
3 years of figures
Amounts in USD. Hover a ratio’s name for its definition.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Income statement | |||
| Research and development | $0.1M | — | $1.6M |
| Operating income | −$0.7M | −$1.3M | −$11.9M |
| Interest expense | $0.0M | $0.1M | $0.3M |
| Net income | −$0.8M | −$1.4M | −$6.0M |
| Diluted EPS | −$0.17 | −$0.18 | −$0.55 |
| Diluted shares | — | 0.01B | 0.01B |
| Cash flow | |||
| Cash from operations | −$0.6M | −$0.7M | −$8.9M |
| Capital expenditure | — | — | $0.1M |
| Free cash flow | — | — | −$9.0M |
| Depreciation and amortization | — | — | $0.0M |
| Stock-based compensation | $0.1M | $0.1M | $1.6M |
| Acquisitions | — | — | −$0.0M |
| Balance sheet | |||
| Cash and short-term investments | $0.4M | $0.0M | $3.6M |
| Deposits | — | — | $8.0M |
| Current assets | $0.4M | $0.0M | $14.0M |
| Current liabilities | $0.1M | $1.0M | $10.7M |
| Property and equipment, net | — | — | $0.1M |
| Total assets | $0.4M | $0.0M | $164M |
| Total liabilities | $0.4M | $1.4M | $10.8M |
| Preferred stock | — | — | $0.0M |
| Shareholders' equity | $0.0M | −$1.4M | $153M |
| Returns | |||
| Return on capital employed | −250.1% | 126.1% | −7.8% |
| Return on equity | −2,437.9% | — | −7.9% |
| Return on assets | −184.2% | −638.8% | −7.3% |
| Return on tangible equity | −2,437.9% | — | −3.9% |
| Growth | |||
| Share count change | — | — | 37.7% |
| Financial health | |||
| Interest coverage | −19.6x | −10.8x | −42.1x |
| Current ratio | 3.4x | 0.0x | 1.3x |
| Quick ratio | 3.4x | 0.0x | 1.3x |
| Quality scores | |||
| Altman Z'' | −30.4 | −2,254.5 | 14.3 |
| Accruals ratio | −35.5% | −301.7% | 3.6% |
Source: SEC EDGAR XBRL filings (CIK 0001894525). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.